Get the Stockscreener App
2.18
4.09%
0.10
Actuate Therapeutics Inc stock is traded at $2.18, with a volume of 309.79K.
It is up +4.09% in the last 24 hours and down -15.43% over the past month.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
See More
Previous Close:
$2.08
Open:
$2.14
24h Volume:
309.79K
Relative Volume:
3.63
Market Cap:
$50.98M
Revenue:
-
Net Income/Loss:
$-22.23M
P/E Ratio:
-2.0272
EPS:
-1.0754
Net Cash Flow:
$-19.21M
1W Performance:
+12.76%
1M Performance:
-15.43%
6M Performance:
-72.35%
1Y Performance:
-72.77%
1-Day Range:
$2.045
$2.59
1-Week Range:
$1.58
$2.59
52-Week Range:
$1.58
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Name
Actuate Therapeutics Inc
Sector
Industry
Phone
847-986-4190
Address
1751 RIVER RUN, FORT WORTH
Compare ACTU vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
2.15 | 49.32M | 0 | -22.23M | -19.21M | -1.0754 |
VRTX
Vertex Pharmaceuticals Inc
|
442.10 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.74 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
843.15 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
334.95 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
317.52 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-26-25 | Initiated | B. Riley Securities | Buy |
| Apr-22-25 | Initiated | Craig Hallum | Buy |
| Mar-17-25 | Initiated | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Stock (ACTU) Latest News
B.Riley cuts Actuate Therapeutics stock price target on revenue timing - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Actuate Therapeutics Reports Significant Survival Improvement in Phase 2 Trial of Elraglusib for Metastatic Pancreatic Cancer - Quiver Quantitative
Pancreatic cancer trial doubled one-year survival in study - Stock Titan
ACTU Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Cuts Target Price to $15 - Moomoo
Netflix To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
H.C. Wainwright lowers Actuate Therapeutics price target on strategy shift By Investing.com - Investing.com Canada
H.C. Wainwright lowers Actuate Therapeutics price target on strategy shift - Investing.com
Activity Recap: Can Actuate Therapeutics Inc scale operations efficiently2026 Price Action Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Published on: 2026-04-09 23:48:44 - baoquankhu1.vn
Aug Levels: Does Actuate Therapeutics Inc have consistent dividend growth2026 Intraday Action & Community Consensus Trade Signals - baoquankhu1.vn
Profit Review: Is Actuate Therapeutics Inc benefiting from innovation trendsWeekly Trade Analysis & Consistent Return Strategy Ideas - baoquankhu1.vn
Actuate Therapeutics (NASDAQ:ACTU) Raised to Hold at Wall Street Zen - MarketBeat
ACTU Technical Analysis & Stock Price Forecast - Intellectia AI
Aug Setups: Is Actuate Therapeutics Inc stock showing strong momentum2026 Short Interest & Accurate Intraday Trading Signals - baoquankhu1.vn
Actuate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Actuate Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers - Finviz
Aug Levels: Is Actuate Therapeutics Inc benefiting from innovation trends2026 Retail & Safe Entry Point Identification - baoquankhu1.vn
Aug Outlook: Can Actuate Therapeutics Inc scale operations efficiently2026 Selloffs & Entry Point Confirmation Signals - baoquankhu1.vn
Actuate Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | ACTU | US0050831009 - marketscreener.com
Aug Shorts: Can Actuate Therapeutics Inc outperform under higher oil pricesWeekly Trade Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
Voss Capital LP Boosts Stake in Actuate Therapeutics, Inc. $ACTU - MarketBeat
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% - MSN
Actuate Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors - Bitget
RSI Check: Is Actuate Therapeutics Inc stock showing strong momentumWeekly Investment Recap & Safe Capital Growth Stock Tips - baoquankhu1.vn
Actuate Therapeutics files $250M mixed securities shelf - MSN
Will Actuate Therapeutics Inc. stock gain from lower inflationPortfolio Update Summary & Reliable Price Breakout Signals - Naître et grandir
Actuate Therapeutics (NASDAQ:ACTU) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Activity Recap: How buybacks impact Actuate Therapeutics Inc. stock valueMarket Weekly Review & Safe Capital Allocation Plans - Naître et grandir
Actuate Therapeutics to Present at The Citizens Life Sciences Conference - Bitget
Actuate Therapeutics, Inc. Announces Presentation at Citizens Life Sciences Conference in Miami Beach - Quiver Quantitative
Actuate Therapeutics to Present at The Citizens Life Sciences Conference - GlobeNewswire Inc.
ACTUActuate Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
ACTU Technical Analysis & ETF Price Forecast - Intellectia AI
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Manila Times
Actuate Therapeutics, Inc. to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 - Quiver Quantitative
ACTU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is Actuate Therapeutics Inc. stock undervalued right nowMarket Performance Report & Daily Stock Trend Watchlist - mfd.ru
Actuate Therapeutics (NASDAQ:ACTU) Rating Increased to Hold at Wall Street Zen - Defense World
ACTU PE Ratio & Valuation, Is ACTU Overvalued - Intellectia AI
Is Actuate Therapeutics Inc. stock risky to hold nowPortfolio Update Report & Technical Confirmation Trade Alerts - mfd.ru
A | Will SIMAU announce a stock splitJuly 2025 Trends & Stepwise Entry and Exit Trade Signals - mfd.ru
Actuate Therapeutics (NASDAQ:ACTU) Shares Down 3.6%Here's What Happened - MarketBeat
What is the long term forecast for GATES GROUP Inc. stockJuly 2025 Selloffs & AI Enhanced Trading Signals - baoquankhu1.vn
Published on: 2026-02-07 16:03:44 - baoquankhu1.vn
Actuate Therapeutics registers 1.33M shares for resale by investors - MSN
Patterns Watch: Is Actuate Therapeutics Inc benefiting from innovation trendsJuly 2025 Sentiment & Risk Managed Investment Entry Signals - baoquankhu1.vn
Decliners Report: Is Actuate Therapeutics Inc benefiting from innovation trendsBreakout Watch & Daily Profit Maximizing Tips - baoquankhu1.vn
Actuate Therapeutics Inc Stock (ACTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Actuate Therapeutics Inc Stock (ACTU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| THOMSON TODD S | Director |
Jan 05 '26 |
Sale |
5.80 |
280,000 |
1,624,000 |
904,795 |
2.68%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):